Published in Hepatitis Weekly, March 14th, 2005
The investigator-sponsored trial is being conducted at specialist centers in Europe and Egypt and will assess the ability of Virostat to reduce viral load and improve quality of life in patients with chronic hepatitis C.
"This begins a new phase of development for Bioenvision, and we look forward to the opportunity to build value in our non-cancer related franchises," said Chris Wood, chairman and CEO of Bioenvision. He added,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.